Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) EV-to-EBIT : -20.12 (As of Apr. 26, 2024)

Dicerna Pharmaceuticals EV-to-EBIT Chart

Dicerna Pharmaceuticals Annual Data
	Trend	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
EV-to-EBIT		Get a 7-Day Free Trial					-0.23	-5.86	-4.83	-10.39	-10.22

Dicerna Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
EV-to-EBIT	Get a 7-Day Free Trial															-6.88	-10.22	-12.19	-18.41	-8.68

Competitive Comparison of Dicerna Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Dicerna Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dicerna Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dicerna Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dicerna Pharmaceuticals's EV-to-EBIT falls into.

Dicerna Pharmaceuticals EV-to-EBIT Calculation

Dicerna Pharmaceuticals's EV-to-EBIT for today is calculated as:

Dicerna Pharmaceuticals's current Enterprise Value is $2,476.6 Mil.
Dicerna Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dicerna Pharmaceuticals  (NAS:DRNA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Dicerna Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2021 is calculated as:

Dicerna Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2021 was $1,068.1 Mil.
Dicerna Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dicerna Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description